clobazam has been researched along with Epilepsy in 158 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration." | 9.41 | Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. ( Biton, V; Carrazana, E; Cascino, GD; Cook, DF; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| "Evaluation of the efficacy and side effects profile of Clobazam in a 24-week open-labelled trial involving 26 cases of drug naïve adult patients with epilepsy." | 9.10 | Clobazam monotherapy in drug naïve adult patients with epilepsy. ( Krishnamurthy, M; Mehndiratta, MM; Rajesh, KN; Singh, G, 2003) |
| "To compare the cognitive and behavioural effects of clobazam versus standard monotherapy in the treatment of childhood epilepsy." | 9.09 | The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. ( Bawden, HN; Camfield, CS; Camfield, PR; Cunningham, C; Darwish, H; Dooley, JM; Gordon, K; Ronen, G; Stewart, J; van Mastrigt, R, 1999) |
| "To compare the effectiveness of monotherapy clobazam (CLB) to carbamazepine (CBZ) and phenytoin (PHT) in children with epilepsy." | 9.08 | Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. ( , 1998) |
| "Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder." | 9.07 | Aggression in children treated with clobazam for epilepsy. ( Goulden, KJ; Ronen, GM; Sheth, RD, 1994) |
| "Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types." | 9.06 | Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. ( Blaschuk, K; Couture, M; Guberman, A; Sherwin, A, 1990) |
| "We report the results of a double-blind cross-over study comparing clobazam and placebo in the treatment of refractory childhood epilepsy." | 9.06 | Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. ( Humphreys, P; Keene, DL; Whiting, S, 1990) |
| "The cyclical exacerbations of epilepsy (catamenial epilepsy) were used to assess the antiepileptic effect of a benzodiazepine, clobazam." | 9.05 | Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. ( Calvert, R; Feely, M; Gibson, J, 1982) |
| "The literature was reviewed to define the role of clobazam (CLB) in the treatment of epilepsy." | 8.79 | Clobazam in the treatment of epilepsy: a review of the literature. ( Remy, C, 1994) |
| "Clobazam (CLB), a 1,5-benzodiazepine, is a remarkably effective add-on drug for individual patients with refractory partial epilepsy." | 8.79 | Clobazam for treatment of intractable epilepsy: a critical assessment. ( Schmidt, D, 1994) |
| "To prospectively study the effectiveness and safety of clobazam as an add-on therapy in patients with epilepsy whose seizures are not adequately controlled with antiseizure medicine (ASM) monotherapy." | 8.12 | Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience. ( Agadi, J; Agarwal, VK; Alagesan, S; Apte, A; Arora, V; Asokan, K; Chauhan, D; Chodankar, D; Garg, S; Gurumukhani, J; Jha, SK; Kumar, A; Lingappa, L; Mandal, A; Menon, B; Padhy, U; Rathore, C; Ravat, S; Razdan, S; Satishchandra, P; Shah, SV; Shetty, S; Sundaracharya, NV; Venkateshwarlu, K; Vk, S, 2022) |
| " We review the use of short burst Clobazam dosing on discharge from the Epilepsy monitoring unit (EMU) to determine if this might reduce rates of representation with seizures." | 7.91 | Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures. ( Dionisio, S; Gillinder, L; Scarborough, L, 2019) |
| "Adult patients from Calgary's Comprehensive Epilepsy Program who were taking clobazam were approached to participate in the study." | 7.88 | A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy. ( Altura, KC; Jetté, N; Josephson, CB; Lukmanji, S; Sauro, KM; Wiebe, S, 2018) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 7.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "To compare patient characteristics and treatment patterns among clobazam (CLB) and clonazepam (CZP)-treated patients with epilepsy in a longitudinal primary care database." | 7.83 | Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study. ( Brodie, MJ; Chung, S; François, C; Guiraud-Diawara, A; Isojarvi, J; Quelen, C; Shen, V; Verpillat, P; Wade, A, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 7.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| "Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children." | 7.81 | Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. ( Bruno, PL; Geffrey, AL; Pollack, SF; Thiele, EA, 2015) |
| "Clobazam has been used in clinical practice as an adjunctive treatment for diverse seizure types and epilepsy syndromes." | 7.80 | Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. ( Bergin, AM; Bolton, J; Bourgeois, B; Harini, C; Kadish, NE; Klehm, J; Libenson, M; Loddenkemper, T; Peters, J; Poduri, A; Rotenberg, A; Sánchez Fernández, I; Takeoka, M; Thome-Souza, S, 2014) |
| "The use of clobazam in epilepsy has increased since its introduction in 1975." | 7.80 | Effect of clobazam as add-on antiepileptic drug in patients with epilepsy. ( Gupta, P; Gupta, YK; Joshi, R; Tripathi, M, 2014) |
| "In treating refractory epilepsy, many clinicians are interested in methods used to transition patients receiving clonazepam to clobazam to maintain or increase seizure control, improve tolerability of patients' overall drug therapy regimens, and to enhance quality of life for patients and their families." | 7.80 | Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. ( Chung, S; Kuzniecky, R; Perry, MS; Sankar, R; Sinha, S, 2014) |
| "Clobazam (CLB) was recently approved by the FDA, but has not been evaluated in tuberous sclerosis complex (TSC)." | 7.79 | Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. ( Caruso, PA; Jennesson, M; Paolini, JL; Thiele, EA; van Eeghen, AM, 2013) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "To evaluate the efficacy of clobazam in childhood refractory epilepsy and to characterize the adverse drug reaction profile in the Indian population." | 7.76 | Clobazam in refractory childhood epilepsy. ( Kalra, V; Mishra, D; Saha, NC; Seth, R, 2010) |
| "A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0." | 7.73 | Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. ( Aylett, SE; Berry, D; Cross, H, 2006) |
| " We report the first case observed in association with clobazam, used as adjunctive therapy for resistant epilepsy in a 4-year old." | 7.70 | Coma-induced bullae and sweat gland necrosis following clobazam. ( Calonje, E; MacDonald, D; Robinson, R; Setterfield, JF, 2000) |
| "Clobazam is a newer 1,5-benzodiazepine used for the treatment of epilepsy." | 7.70 | Clobazam for the treatment of intractable childhood epilepsy. ( Jan, MM; Shaabat, AO, 2000) |
| "We report our experience with add-on clobazam therapy over a 5-year period in 63 children with refractory epilepsy." | 7.69 | Clobazam for intractable pediatric epilepsy. ( Bodensteiner, JB; Goulden, KJ; Penney, S; Ronen, GM; Sheth, RD, 1995) |
| "We retrospectively collected plasma level assessments performed in 96 adult patients with epilepsy on stable monotherapy, including 9 patients on clobazam (CLB), 34 on carbamazepine (CBZ), 24 on phenobarbital (PB), 9 on phenytoin (PHT), and 20 on valproate (VPA); these results were compared to those obtained in 54 adult patients on stable bitherapy with the association of CLB with either CBZ (n = 17), PB (n = 17), PHT (n = 5), or VPA (n = 15)." | 7.68 | Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. ( Bonneton, J; Dravet, C; Genton, P; Mesdjian, E; Roger, J; Sennoune, S, 1992) |
| "Clobazam was added to the previous antiepileptic drug therapy of 90 children suffering from drug resistant epilepsy." | 7.68 | Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. ( Bardy, AH; Granström, ML; Salokorpi, T; Santavuori, P; Seppälä, T, 1991) |
| "Thirty drug-resistant epilepsy patients were given 20-30 mg of clobazam in addition to their other anticonvulsants and followed up for 2-3 years in an open-ended study." | 7.67 | The long-term effect of clobazam as adjunctive therapy in epilepsy. ( Moffett, A; Scott, DF, 1988) |
| "Sixteen patients with status epilepticus (SE) and 13 patients suffering from startle-induced epilepsy were treated with clobazam (CLB)." | 7.67 | Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1986) |
| " The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy." | 7.01 | Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023) |
| " Steady-state pharmacokinetic data are described from four healthy male volunteers and eight epileptic patients taking NDMC." | 6.66 | Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. ( Feely, MP; Haigh, JR; Peaker, S; Pullar, T, 1987) |
| "Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA." | 6.52 | Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. ( Gauthier, AC; Mattson, RH, 2015) |
| "Clobazam is a promising antiepileptic medication, given its effectiveness and relatively low rates of adverse effects." | 6.48 | Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. ( Ng, YT; Seif-Eddeine, H, 2012) |
| "Clobazam as an add-on treatment may reduce seizure frequency and may be most effective in partial onset seizures." | 6.44 | Clobazam as an add-on in the management of refractory epilepsy. ( Marson, AG; Michael, B, 2008) |
| "Several studies suggest antiseizure effects also beyond these three epilepsy syndromes." | 5.91 | Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023) |
| "The average number of seizures per month during the previous 3 months before CNB treatment was 19." | 5.91 | Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023) |
| "Here, one such patient became seizure free, allowing us to identify and compare the changes in hippocampal electrophysiology associated with ANT stimulation and seizure freedom." | 5.91 | Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023) |
| "Clobazam is an effective agent to use as add-on AED in TRE, with 94% of patients showing a significant response within 6 months." | 5.62 | Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. ( Bachman, E; Brahmbhatt, N; Bushara, O; Schuele, SU; Stupp, R; Templer, JW, 2021) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 5.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| "Pharmacokinetic variability of CLB in pediatric patients is extensive, and it is influenced by drug-drug interactions and age." | 5.48 | Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy. ( Phelps, SJ; Russell, GR; Shelton, CM; Wheless, JW, 2018) |
| "5 mg/day) and dosage increased until N-CLB serum concentration reaches 1100 ng/mL or until the desired effect is acquired, a recommendation that is particularly important for PMs." | 5.42 | Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. ( Hashi, S; Ikeda, A; Kinoshita, M; Masuda, S; Matsubara, K; Matsumoto, R; Shibata, M; Takahashi, R; Yano, I, 2015) |
| "Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration." | 5.41 | Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. ( Biton, V; Carrazana, E; Cascino, GD; Cook, DF; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| "Clobazam (CLB) is a 1,5-benzodiazepine with antiepileptic properties." | 5.40 | Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. ( Ishitsu, T; Kaneko, S; Nagata, R; Nakagawa, K; Nakashima, H; Nishimura, M; Ogusu, N; Saruwatari, J; Seo, T; Shimomasuda, M; Tanikawa, K; Tsuda, Y; Yasui-Furukori, N, 2014) |
| "Clobazam has efficacy against a wide spectrum of seizure types and epilepsy etiologies." | 5.39 | Clobazam for the treatment of intractable epilepsy in children. ( Bailey, L; Gilson, C; Hernandez, A; Kotecha, A; Malik, S; Perry, MS, 2013) |
| "Clobazam (CLB) is a structurally unique benzodiazepine (BZD) that has anticonvulsant activity in all types of refractory seizures." | 5.29 | Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. ( Boisvert, D; Guberman, AH; Singh, A, 1995) |
| " Cannabidiol (CBD) is increasingly used to treat epilepsy." | 5.12 | Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients. ( Główka, AK; Główka, FK; Karaźniewicz-Łada, M; Mikulska, AA, 2021) |
| "Evaluation of the efficacy and side effects profile of Clobazam in a 24-week open-labelled trial involving 26 cases of drug naïve adult patients with epilepsy." | 5.10 | Clobazam monotherapy in drug naïve adult patients with epilepsy. ( Krishnamurthy, M; Mehndiratta, MM; Rajesh, KN; Singh, G, 2003) |
| "To compare the cognitive and behavioural effects of clobazam versus standard monotherapy in the treatment of childhood epilepsy." | 5.09 | The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy. ( Bawden, HN; Camfield, CS; Camfield, PR; Cunningham, C; Darwish, H; Dooley, JM; Gordon, K; Ronen, G; Stewart, J; van Mastrigt, R, 1999) |
| "To compare the effectiveness of monotherapy clobazam (CLB) to carbamazepine (CBZ) and phenytoin (PHT) in children with epilepsy." | 5.08 | Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. ( , 1998) |
| "Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder." | 5.07 | Aggression in children treated with clobazam for epilepsy. ( Goulden, KJ; Ronen, GM; Sheth, RD, 1994) |
| "Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types." | 5.06 | Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. ( Blaschuk, K; Couture, M; Guberman, A; Sherwin, A, 1990) |
| "We report the results of a double-blind cross-over study comparing clobazam and placebo in the treatment of refractory childhood epilepsy." | 5.06 | Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. ( Humphreys, P; Keene, DL; Whiting, S, 1990) |
| "The cyclical exacerbations of epilepsy (catamenial epilepsy) were used to assess the antiepileptic effect of a benzodiazepine, clobazam." | 5.05 | Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. ( Calvert, R; Feely, M; Gibson, J, 1982) |
| "The literature was reviewed to define the role of clobazam (CLB) in the treatment of epilepsy." | 4.79 | Clobazam in the treatment of epilepsy: a review of the literature. ( Remy, C, 1994) |
| "Clobazam (CLB), a 1,5-benzodiazepine, is a remarkably effective add-on drug for individual patients with refractory partial epilepsy." | 4.79 | Clobazam for treatment of intractable epilepsy: a critical assessment. ( Schmidt, D, 1994) |
| " Clonazepam, chlorazepate, nitrazepam and clobazam are also prescribed as chronic treatment of various forms of epilepsy." | 4.76 | [Benzodiazepines in the treatment of epilepsy]. ( Loiseau, P, 1983) |
| "We identified a significant decrease in the serum concentrations of clobazam, desmethylclobazam, and lamotrigine following a 12-week ketogenic diet intervention in children with drug resistant epilepsy." | 4.31 | Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet. ( Gervin, K; Iversen, PO; Kverneland, M; Landmark, CJ; Pedersen, S; Rudi, K; Selmer, KK, 2023) |
| "To prospectively study the effectiveness and safety of clobazam as an add-on therapy in patients with epilepsy whose seizures are not adequately controlled with antiseizure medicine (ASM) monotherapy." | 4.12 | Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience. ( Agadi, J; Agarwal, VK; Alagesan, S; Apte, A; Arora, V; Asokan, K; Chauhan, D; Chodankar, D; Garg, S; Gurumukhani, J; Jha, SK; Kumar, A; Lingappa, L; Mandal, A; Menon, B; Padhy, U; Rathore, C; Ravat, S; Razdan, S; Satishchandra, P; Shah, SV; Shetty, S; Sundaracharya, NV; Venkateshwarlu, K; Vk, S, 2022) |
| "Clobazam (CLB) is an effective anticonvulsant used as an adjunctive treatment for several seizures and epilepsy syndromes." | 4.12 | CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up. ( Öztürk, G; Türkdoğan, D, 2022) |
| " We review the use of short burst Clobazam dosing on discharge from the Epilepsy monitoring unit (EMU) to determine if this might reduce rates of representation with seizures." | 3.91 | Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures. ( Dionisio, S; Gillinder, L; Scarborough, L, 2019) |
| "Adult patients from Calgary's Comprehensive Epilepsy Program who were taking clobazam were approached to participate in the study." | 3.88 | A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy. ( Altura, KC; Jetté, N; Josephson, CB; Lukmanji, S; Sauro, KM; Wiebe, S, 2018) |
| "Serum concentration measurements of CLB and its metabolite N-desmethylclobazam (NCLB), as well as demographic and clinical data were retrieved from the routine therapeutic drug monitoring service at the National Center for Epilepsy, Norway, 2009-2013." | 3.83 | Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. ( Baftiu, A; Burns, ML; Johannessen, SI; Landmark, CJ; Opdal, MS, 2016) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 3.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "To compare patient characteristics and treatment patterns among clobazam (CLB) and clonazepam (CZP)-treated patients with epilepsy in a longitudinal primary care database." | 3.83 | Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study. ( Brodie, MJ; Chung, S; François, C; Guiraud-Diawara, A; Isojarvi, J; Quelen, C; Shen, V; Verpillat, P; Wade, A, 2016) |
| "The alterations observed in body composition with valproic acid in contrast to other AEDs like levetiracetam, carbamazepine and phenytoin could affect treatment response in epilepsy especially in subjects with already altered body composition status like obese and thin frail patients, which needs to be established by prospective studies (CTRI/2013/05/003701)." | 3.83 | Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. ( Gupta, YK; Kakkar, AK; Sarangi, SC; Tripathi, M, 2016) |
| "Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam." | 3.81 | Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015) |
| "Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children." | 3.81 | Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. ( Bruno, PL; Geffrey, AL; Pollack, SF; Thiele, EA, 2015) |
| "Clobazam has been used in clinical practice as an adjunctive treatment for diverse seizure types and epilepsy syndromes." | 3.80 | Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. ( Bergin, AM; Bolton, J; Bourgeois, B; Harini, C; Kadish, NE; Klehm, J; Libenson, M; Loddenkemper, T; Peters, J; Poduri, A; Rotenberg, A; Sánchez Fernández, I; Takeoka, M; Thome-Souza, S, 2014) |
| "The use of clobazam in epilepsy has increased since its introduction in 1975." | 3.80 | Effect of clobazam as add-on antiepileptic drug in patients with epilepsy. ( Gupta, P; Gupta, YK; Joshi, R; Tripathi, M, 2014) |
| "In treating refractory epilepsy, many clinicians are interested in methods used to transition patients receiving clonazepam to clobazam to maintain or increase seizure control, improve tolerability of patients' overall drug therapy regimens, and to enhance quality of life for patients and their families." | 3.80 | Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. ( Chung, S; Kuzniecky, R; Perry, MS; Sankar, R; Sinha, S, 2014) |
| "Clobazam (CLB) was recently approved by the FDA, but has not been evaluated in tuberous sclerosis complex (TSC)." | 3.79 | Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. ( Caruso, PA; Jennesson, M; Paolini, JL; Thiele, EA; van Eeghen, AM, 2013) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "To evaluate the efficacy of clobazam in childhood refractory epilepsy and to characterize the adverse drug reaction profile in the Indian population." | 3.76 | Clobazam in refractory childhood epilepsy. ( Kalra, V; Mishra, D; Saha, NC; Seth, R, 2010) |
| "To assess the molecular effects of the antiepileptic drug clobazam (CLB, 1,5-benzodiazepine), a benzodiazepine effective in the management of epilepsy, we performed a series of experiments using rats with chronic, spontaneous recurrent seizures induced by amygdalar injection of FeCl(3)." | 3.73 | Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. ( Doi, T; Tokumaru, J; Ueda, Y; Willmore, LJ, 2005) |
| "Clobazam has been used successfully in adults and children with partial epilepsy." | 3.73 | Clobazam as add-on therapy in children with epileptic encephalopathy. ( Guerreiro, CA; Guerreiro, MM; Montenegro, MA; Silva, RC, 2006) |
| "A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0." | 3.73 | Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. ( Aylett, SE; Berry, D; Cross, H, 2006) |
| "Morning urine samples were collected from children with epilepsy receiving VPA (n = 25), carbamazepine (n = 16), or clobazam (n = 12) for > or = 4 weeks and from age-matched control subjects (n = 39)." | 3.73 | Oxidative stress in children receiving valproic acid. ( Abbott, FS; Chang, TK; Farrell, K; Michoulas, A; Teng, XW; Tong, V, 2006) |
| " We report the first case observed in association with clobazam, used as adjunctive therapy for resistant epilepsy in a 4-year old." | 3.70 | Coma-induced bullae and sweat gland necrosis following clobazam. ( Calonje, E; MacDonald, D; Robinson, R; Setterfield, JF, 2000) |
| "Clobazam is a newer 1,5-benzodiazepine used for the treatment of epilepsy." | 3.70 | Clobazam for the treatment of intractable childhood epilepsy. ( Jan, MM; Shaabat, AO, 2000) |
| "We report our experience with add-on clobazam therapy over a 5-year period in 63 children with refractory epilepsy." | 3.69 | Clobazam for intractable pediatric epilepsy. ( Bodensteiner, JB; Goulden, KJ; Penney, S; Ronen, GM; Sheth, RD, 1995) |
| "The development of tolerance to the anticonvulsant effects of clonazepam, clobazam, and diazepam were studied in genetically epilepsy-prone rats following intraperitoneal (IP) or oral administration." | 3.69 | Tolerance to anticonvulsant effects of some benzodiazepines in genetically epilepsy prone rats. ( Aguglia, U; de Sarro, A; De Sarro, G; Di Paola, ED, 1996) |
| "We present the study of 20 pediatric patients with difficult controlled epilepsy in which we used clobazam as adjuvant anticonvulsant therapy between January 1986 and July 1990 at the outpatients neuropediatric facility of the Hospital General Base Cayetano Heredia and the private practice, with 6 to 45 months follow up." | 3.68 | [Clobazam use in refractory epilepsies in children]. ( Campos, P, 1993) |
| "We retrospectively collected plasma level assessments performed in 96 adult patients with epilepsy on stable monotherapy, including 9 patients on clobazam (CLB), 34 on carbamazepine (CBZ), 24 on phenobarbital (PB), 9 on phenytoin (PHT), and 20 on valproate (VPA); these results were compared to those obtained in 54 adult patients on stable bitherapy with the association of CLB with either CBZ (n = 17), PB (n = 17), PHT (n = 5), or VPA (n = 15)." | 3.68 | Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. ( Bonneton, J; Dravet, C; Genton, P; Mesdjian, E; Roger, J; Sennoune, S, 1992) |
| "Tolerance to the anticonvulsant effects of clobazam has been studied in three murine models of epilepsy: pentylenetetrazole- and N-methyl-D,L-aspartic acid-induced seizures and audiogenic-induced seizures in the DBA/2 strain." | 3.68 | Tolerance to the anticonvulsant effects of clobazam in mice. ( Pleuvry, BJ; Wildin, JD, 1992) |
| "Clobazam was added to the previous antiepileptic drug therapy of 90 children suffering from drug resistant epilepsy." | 3.68 | Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. ( Bardy, AH; Granström, ML; Salokorpi, T; Santavuori, P; Seppälä, T, 1991) |
| "Oxiracetam, a nootropic drug, could be of potential use in the treatment of memory disturbances in patients with epilepsy who are using antiepileptic drugs." | 3.68 | Pilot study to determine the interaction of oxiracetam with antiepileptic drugs. ( Meijer, JW; van Emde Boas, W; van Wieringen, A; Vermeij, TA, 1990) |
| "Thirty drug-resistant epilepsy patients were given 20-30 mg of clobazam in addition to their other anticonvulsants and followed up for 2-3 years in an open-ended study." | 3.67 | The long-term effect of clobazam as adjunctive therapy in epilepsy. ( Moffett, A; Scott, DF, 1988) |
| "Sixteen patients with status epilepticus (SE) and 13 patients suffering from startle-induced epilepsy were treated with clobazam (CLB)." | 3.67 | Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1986) |
| "Preliminary studies of patients who had brain damage, intractable epilepsy, and mental subnormality showed that clobazam in small doses (20 to 30 mg/day) was beneficial, and indicated that a more detailed investigation was worthwhile." | 3.67 | On the anticonvulsant and psychotropic properties of clobazam--a preliminary study. ( Moffett, A; Scott, DF, 1986) |
| " The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy." | 3.01 | Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023) |
| "Clobazam was well tolerated and reduced drop seizure rates; high-dose CLB was more effective than low-dose CLB." | 2.74 | Clobazam in the treatment of Lennox-Gastaut syndrome. ( Abdulnabi, R; Collins, SD; Conry, JA; Kernitsky, L; Kormany, WN; Mitchell, WG; Ng, YT; Paolicchi, JM; Riley, B; Ritter, FJ; Stolle, J; Tracy, K, 2009) |
| "Clobazam was used as an added treatment in 28 patients with intractable epilepsies: 26 subjects had associated handicaps." | 2.66 | Intractable epilepsies. An open trial with Clobazam. ( Cattabeni, G; Cerisola, N; Cornaggia, CM; Leozappa, C; Manghi, E; Mascetti, PL; Massironi, R; Porro, G, 1989) |
| " Steady-state pharmacokinetic data are described from four healthy male volunteers and eight epileptic patients taking NDMC." | 2.66 | Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy. ( Feely, MP; Haigh, JR; Peaker, S; Pullar, T, 1987) |
| "Clobazam has nitrogen radicals in positions 1 and 5." | 2.65 | Antiepileptic effects of clobazam in children. ( Abe, J; Futagi, Y; Kamio, M; Kato, M; Mimaki, T; Onoe, S; Shimizu, H; Sugita, T; Sumi, K; Tagawa, T; Yabuuchi, H; Yamatodani, A, 1982) |
| "Clobazam is an oral 1,5-benzodiazepine used worldwide for the treatment of many types of epilepsies, although it is currently only approved for Lennox-Gastaut syndrome in the USA." | 2.52 | Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. ( Gauthier, AC; Mattson, RH, 2015) |
| "Clobazam is a promising antiepileptic medication, given its effectiveness and relatively low rates of adverse effects." | 2.48 | Clobazam for patients with Lennox-Gastaut syndrome and epilepsy. ( Ng, YT; Seif-Eddeine, H, 2012) |
| "Clobazam has demonstrated clinical benefit and has been administered safely in more than 50 European studies in which data were reported on greater than 3000 pediatric and adult patients with epilepsy, 300 of whom were diagnosed with LGS; therefore, its use is now being investigated in the U." | 2.44 | Clobazam. ( Collins, SD; Ng, YT, 2007) |
| "Clobazam as an add-on treatment may reduce seizure frequency and may be most effective in partial onset seizures." | 2.44 | Clobazam as an add-on in the management of refractory epilepsy. ( Marson, AG; Michael, B, 2008) |
| "The former consists mainly of severe myoclonic epilepsy in infancy (SMEN), in which patients exhibit seizures from the middle of the first year of life with repeated episodes of status epilepticus, and migrating partial epilepsy in infancy, in which, from the first trimester of life, partial seizures affect various areas of the cortex randomly and in a subcontinuous fashion." | 2.41 | Epileptic encephalopathy. ( Dulac, O, 2001) |
| "Clobazam (CLB) is a new antiepileptic drug that is the first 1,5-benzodiazepine (BZP) having nitrogen atoms in the 1 and 5 positions of the heterocyclic ring, whose chemical structure was designed to give it a different pharmacological profile from that of 1,4-BZPs." | 2.41 | [A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. ( Nakajima, H, 2001) |
| "Several studies suggest antiseizure effects also beyond these three epilepsy syndromes." | 1.91 | Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023) |
| "The average number of seizures per month during the previous 3 months before CNB treatment was 19." | 1.91 | Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023) |
| "Here, one such patient became seizure free, allowing us to identify and compare the changes in hippocampal electrophysiology associated with ANT stimulation and seizure freedom." | 1.91 | Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023) |
| "A positive response (seizure-free and >50 % seizure reduction) was determined for focal-onset (62." | 1.72 | The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study. ( Arslan, EA; Aydın, K; Cansu, A; Çarman, KB; Dilber, B; Dündar, NO; Durgut, BD; Erdoğan, I; Gencpinar, P; Hız, SA; Kamaşak, T; Kılıç, BA; Okuyaz, Ç; Özen, N; Özkan Kart, P; Polat, BG; Şahin, S; Serdaroğlu, A; Serdaroğlu, E; Serin, HM; Tekgül, H; Topçu, Y; Yıldız, N; Yılmaz, Ö; Yücel Şen, AD, 2022) |
| " VPA showed a relatively short half-life in both mice and rats, which correlated with a sharp decline in efficacy." | 1.72 | Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach. ( Johnson, K; Mensah, JA; Metcalf, CS; Reilly, CA; Rower, JE; Wilcox, KS, 2022) |
| "Clobazam is an effective agent to use as add-on AED in TRE, with 94% of patients showing a significant response within 6 months." | 1.62 | Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. ( Bachman, E; Brahmbhatt, N; Bushara, O; Schuele, SU; Stupp, R; Templer, JW, 2021) |
| " The aim was to use long-term TDM to investigate pharmacokinetic variability of ASMs in these patients." | 1.56 | Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome. ( Bjørnvold, M; Burns, ML; Heger, K; Johannessen Landmark, C; Johannessen, SI; Lund, C; Sætre, E, 2020) |
| "Epilepsy is very difficult to treat and often involves the combination of two or more AEDs." | 1.56 | Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. ( Hayashi, T; Noguchi, Y; Tachi, T; Takaoka, M; Teramachi, H, 2020) |
| "Clobazam is a 1,5-benzodiazepine that has been approved for use, in various parts of the world, as an add-on treatment for seizure disorders and as a treatment for anxiety." | 1.51 | Gestational Exposure to Benzodiazepines, 3: Clobazam and Major Congenital Malformations. ( Andrade, C, 2019) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 1.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| "Pharmacokinetic variability of CLB in pediatric patients is extensive, and it is influenced by drug-drug interactions and age." | 1.48 | Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy. ( Phelps, SJ; Russell, GR; Shelton, CM; Wheless, JW, 2018) |
| "5 mg/day) and dosage increased until N-CLB serum concentration reaches 1100 ng/mL or until the desired effect is acquired, a recommendation that is particularly important for PMs." | 1.42 | Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. ( Hashi, S; Ikeda, A; Kinoshita, M; Masuda, S; Matsubara, K; Matsumoto, R; Shibata, M; Takahashi, R; Yano, I, 2015) |
| "Clobazam (CLB) is a 1,5-benzodiazepine with antiepileptic properties." | 1.40 | Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. ( Ishitsu, T; Kaneko, S; Nagata, R; Nakagawa, K; Nakashima, H; Nishimura, M; Ogusu, N; Saruwatari, J; Seo, T; Shimomasuda, M; Tanikawa, K; Tsuda, Y; Yasui-Furukori, N, 2014) |
| "Psychosis is more common in people with temporal lobe epilepsy than it is in the general population." | 1.39 | Electroconvulsive therapy for psychosis in a patient with epilepsy related to hypothalamic hamartoma. ( Foucher, J; Hirsch, E; Lalanne, L; Ruppert, E; Vidailhet, P; Zimmermann, MA, 2013) |
| "Clobazam has efficacy against a wide spectrum of seizure types and epilepsy etiologies." | 1.39 | Clobazam for the treatment of intractable epilepsy in children. ( Bailey, L; Gilson, C; Hernandez, A; Kotecha, A; Malik, S; Perry, MS, 2013) |
| "Clobazam is a 1,5-benzodiazepine effective in antiepileptic therapy of children and adults." | 1.30 | Interactions of clobazam with conventional antiepileptics in children. ( Cortez, M; Daneman, R; Hwang, P; Koren, G; Menzano, E; Sherwin, AL; Theis, JG, 1997) |
| " Both CBZ and CBZ-epoxide (CBZ-E) blood levels were elevated, and the symptoms resolved quickly when CBZ dosage was reduced and CLB discontinued." | 1.30 | Carbamazepine intoxication with negative myoclonus after the addition of clobazam. ( Genton, P; Mesdjian, E; Nguyen, VH, 1998) |
| "Clobazam (CLB) is a structurally unique benzodiazepine (BZD) that has anticonvulsant activity in all types of refractory seizures." | 1.29 | Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance. ( Boisvert, D; Guberman, AH; Singh, A, 1995) |
| "Clobazam was administered in 13 patients; 15." | 1.27 | Startle-induced epileptic seizures. ( Aguglia, U; Gastaut, H; Tinuper, P, 1984) |
| "Ethosuximide was quantitated by gas chromatography." | 1.27 | Tissue distribution of ethosuximide and clobazam in a seizure related fatality. ( Fraser, AD; Heifetz, SA; Isner, AF, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (23.42) | 18.7374 |
| 1990's | 39 (24.68) | 18.2507 |
| 2000's | 25 (15.82) | 29.6817 |
| 2010's | 38 (24.05) | 24.3611 |
| 2020's | 19 (12.03) | 2.80 |
| Authors | Studies |
|---|---|
| Karaźniewicz-Łada, M | 1 |
| Główka, AK | 1 |
| Mikulska, AA | 1 |
| Główka, FK | 1 |
| Satishchandra, P | 2 |
| Rathore, C | 1 |
| Apte, A | 1 |
| Kumar, A | 1 |
| Mandal, A | 1 |
| Chauhan, D | 1 |
| Agadi, J | 1 |
| Gurumukhani, J | 1 |
| Asokan, K | 1 |
| Venkateshwarlu, K | 1 |
| Lingappa, L | 1 |
| Sundaracharya, NV | 1 |
| Jha, SK | 1 |
| Ravat, S | 1 |
| Vk, S | 1 |
| Garg, S | 1 |
| Shah, SV | 1 |
| Alagesan, S | 1 |
| Razdan, S | 1 |
| Padhy, U | 1 |
| Agarwal, VK | 1 |
| Arora, V | 1 |
| Menon, B | 1 |
| Shetty, S | 1 |
| Chodankar, D | 1 |
| Kamaşak, T | 1 |
| Serdaroğlu, E | 1 |
| Yılmaz, Ö | 1 |
| Kılıç, BA | 1 |
| Polat, BG | 1 |
| Erdoğan, I | 1 |
| Yücel Şen, AD | 1 |
| Özen, N | 1 |
| Durgut, BD | 1 |
| Yıldız, N | 1 |
| Özkan Kart, P | 1 |
| Dilber, B | 1 |
| Arslan, EA | 1 |
| Şahin, S | 1 |
| Topçu, Y | 1 |
| Gencpinar, P | 1 |
| Serin, HM | 1 |
| Hız, SA | 1 |
| Çarman, KB | 1 |
| Dündar, NO | 1 |
| Okuyaz, Ç | 1 |
| Aydın, K | 1 |
| Serdaroğlu, A | 1 |
| Tekgül, H | 1 |
| Cansu, A | 1 |
| Mensah, JA | 1 |
| Johnson, K | 1 |
| Reilly, CA | 1 |
| Wilcox, KS | 1 |
| Rower, JE | 1 |
| Metcalf, CS | 1 |
| Tomson, T | 1 |
| Battino, D | 1 |
| Bromley, R | 1 |
| Kochen, S | 1 |
| Meador, KJ | 1 |
| Pennell, PB | 1 |
| Thomas, SV | 1 |
| Talwar, A | 1 |
| Estes, E | 1 |
| Aparasu, R | 1 |
| Reddy, DS | 1 |
| Kühne, F | 1 |
| Becker, LL | 1 |
| Bast, T | 1 |
| Bertsche, A | 1 |
| Borggraefe, I | 1 |
| Boßelmann, CM | 1 |
| Fahrbach, J | 1 |
| Hertzberg, C | 1 |
| Herz, NA | 1 |
| Hirsch, M | 1 |
| Holtkamp, M | 1 |
| Janello, C | 1 |
| Kluger, GJ | 1 |
| Kurlemann, G | 1 |
| Lerche, H | 1 |
| Makridis, KL | 1 |
| von Podewils, F | 1 |
| Pringsheim, M | 1 |
| Schubert-Bast, S | 1 |
| Schulz, J | 1 |
| Schulze-Bonhage, A | 1 |
| Steinbart, D | 1 |
| Steinhoff, BJ | 1 |
| Strzelczyk, A | 1 |
| Syrbe, S | 1 |
| De Vries, H | 1 |
| Wagner, C | 1 |
| Wagner, J | 1 |
| Wilken, B | 1 |
| Prager, C | 1 |
| Klotz, KA | 1 |
| Kaindl, AM | 1 |
| Riva, A | 1 |
| Roberti, R | 1 |
| D'Onofrio, G | 1 |
| Vari, MS | 1 |
| Amadori, E | 1 |
| De Giorgis, V | 1 |
| Cerminara, C | 1 |
| Specchio, N | 2 |
| Pietrafusa, N | 1 |
| Tombini, M | 1 |
| Assenza, G | 1 |
| Cappanera, S | 1 |
| Marini, C | 1 |
| Rasmini, P | 1 |
| Veggiotti, P | 2 |
| Zara, F | 1 |
| Russo, E | 1 |
| Striano, P | 1 |
| Pedersen, S | 1 |
| Kverneland, M | 1 |
| Rudi, K | 1 |
| Gervin, K | 1 |
| Landmark, CJ | 2 |
| Iversen, PO | 1 |
| Selmer, KK | 1 |
| Serrano-Castro, PJ | 1 |
| Rodríguez-Uranga, JJ | 1 |
| Cabezudo-García, P | 1 |
| García-Martín, G | 1 |
| Romero-Godoy, J | 1 |
| Estivill-Torrús, G | 1 |
| Ciano-Petersen, NL | 1 |
| Oliver, B | 1 |
| Ortega-Pinazo, J | 1 |
| López-Moreno, Y | 1 |
| Aguilar-Castillo, MJ | 1 |
| Gutierrez-Cardo, AL | 1 |
| Ramírez-García, T | 1 |
| Sanchez-Godoy, L | 1 |
| Carreño, M | 1 |
| Skelton, HM | 1 |
| Brandman, DM | 1 |
| Bullinger, K | 1 |
| Isbaine, F | 1 |
| Gross, RE | 1 |
| Andrade, C | 1 |
| Deng, L | 1 |
| Ma, A | 1 |
| Wood, N | 1 |
| Ardern-Holmes, S | 1 |
| Johannessen Landmark, C | 1 |
| Heger, K | 1 |
| Lund, C | 1 |
| Burns, ML | 2 |
| Bjørnvold, M | 1 |
| Sætre, E | 1 |
| Johannessen, SI | 2 |
| VanLandingham, KE | 1 |
| Crockett, J | 1 |
| Taylor, L | 1 |
| Morrison, G | 1 |
| Noguchi, Y | 1 |
| Takaoka, M | 1 |
| Hayashi, T | 1 |
| Tachi, T | 1 |
| Teramachi, H | 1 |
| van den Munckhof, B | 1 |
| Arzimanoglou, A | 1 |
| Perucca, E | 1 |
| van Teeseling, HC | 1 |
| Leijten, FSS | 1 |
| Braun, KPJ | 1 |
| Jansen, FE | 1 |
| Brahmbhatt, N | 1 |
| Stupp, R | 1 |
| Bushara, O | 1 |
| Bachman, E | 1 |
| Schuele, SU | 1 |
| Templer, JW | 1 |
| Türkdoğan, D | 1 |
| Öztürk, G | 1 |
| Segal, EB | 1 |
| Tarquinio, D | 1 |
| Miller, I | 1 |
| Wheless, JW | 2 |
| Dlugos, D | 1 |
| Biton, V | 1 |
| Cascino, GD | 1 |
| Desai, J | 1 |
| Hogan, RE | 1 |
| Liow, K | 1 |
| Sperling, MR | 1 |
| Vazquez, B | 1 |
| Cook, DF | 1 |
| Rabinowicz, AL | 1 |
| Carrazana, E | 1 |
| Gaston, TE | 1 |
| Bebin, EM | 1 |
| Cutter, GR | 1 |
| Liu, Y | 1 |
| Szaflarski, JP | 1 |
| Vega, C | 1 |
| Sánchez Fernández, I | 2 |
| Peters, J | 2 |
| Thome-Souza, MS | 1 |
| Jackson, M | 1 |
| Takeoka, M | 2 |
| Wilkening, GN | 1 |
| Pearl, PL | 1 |
| Chapman, K | 1 |
| Loddenkemper, T | 2 |
| Lukmanji, S | 1 |
| Sauro, KM | 1 |
| Josephson, CB | 1 |
| Altura, KC | 1 |
| Wiebe, S | 1 |
| Jetté, N | 1 |
| Porcari, GS | 1 |
| Fu, C | 1 |
| Doll, ED | 1 |
| Carter, EG | 1 |
| Carson, RP | 1 |
| Skarpaas, TL | 1 |
| Tcheng, TK | 1 |
| Morrell, MJ | 1 |
| Russell, GR | 1 |
| Phelps, SJ | 1 |
| Shelton, CM | 1 |
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| Gillinder, L | 1 |
| Scarborough, L | 1 |
| Dionisio, S | 1 |
| Yamamoto, Y | 3 |
| Takahashi, Y | 3 |
| Imai, K | 3 |
| Miyakawa, K | 1 |
| Nishimura, S | 2 |
| Kasai, R | 1 |
| Ikeda, H | 1 |
| Takayama, R | 1 |
| Mogami, Y | 2 |
| Yamaguchi, T | 1 |
| Terada, K | 2 |
| Matsuda, K | 2 |
| Inoue, Y | 3 |
| Kagawa, Y | 3 |
| Ruppert, E | 1 |
| Lalanne, L | 1 |
| Foucher, J | 1 |
| Zimmermann, MA | 1 |
| Hirsch, E | 1 |
| Vidailhet, P | 1 |
| Saruwatari, J | 1 |
| Ogusu, N | 1 |
| Shimomasuda, M | 1 |
| Nakashima, H | 1 |
| Seo, T | 1 |
| Tanikawa, K | 1 |
| Tsuda, Y | 1 |
| Nishimura, M | 1 |
| Nagata, R | 1 |
| Yasui-Furukori, N | 1 |
| Kaneko, S | 1 |
| Ishitsu, T | 1 |
| Nakagawa, K | 1 |
| Nakai, M | 2 |
| Klehm, J | 1 |
| Thome-Souza, S | 1 |
| Bergin, AM | 1 |
| Bolton, J | 1 |
| Harini, C | 1 |
| Kadish, NE | 1 |
| Libenson, M | 1 |
| Poduri, A | 1 |
| Rotenberg, A | 1 |
| Bourgeois, B | 1 |
| Dilipkumar, S | 1 |
| Subbakrishna, DK | 1 |
| Sinha, S | 2 |
| Takahashi, M | 1 |
| Tan, HJ | 1 |
| Singh, J | 1 |
| Gupta, R | 1 |
| de Goede, C | 1 |
| Guerreiro, CA | 2 |
| Joshi, R | 1 |
| Tripathi, M | 2 |
| Gupta, P | 1 |
| Gupta, YK | 2 |
| Hashi, S | 1 |
| Yano, I | 1 |
| Shibata, M | 1 |
| Masuda, S | 1 |
| Kinoshita, M | 2 |
| Matsumoto, R | 1 |
| Ikeda, A | 2 |
| Takahashi, R | 1 |
| Matsubara, K | 1 |
| Trivisano, M | 1 |
| Vigevano, F | 1 |
| Sankar, R | 1 |
| Chung, S | 2 |
| Perry, MS | 2 |
| Kuzniecky, R | 1 |
| Gauthier, AC | 1 |
| Mattson, RH | 1 |
| Geffrey, AL | 1 |
| Pollack, SF | 1 |
| Bruno, PL | 1 |
| Thiele, EA | 2 |
| Baftiu, A | 1 |
| Opdal, MS | 1 |
| Mathew, T | 1 |
| D'Souza, D | 1 |
| Nadimpally, US | 1 |
| Nadig, R | 1 |
| Takeuchi, T | 1 |
| Natsume, J | 1 |
| Kidokoro, H | 1 |
| Ishihara, N | 1 |
| Yamamoto, H | 1 |
| Azuma, Y | 1 |
| Ito, Y | 1 |
| Kurahashi, N | 1 |
| Tsuji, T | 1 |
| Suzuki, M | 1 |
| Itomi, K | 1 |
| Yamada, K | 1 |
| Kurahashi, H | 1 |
| Abe, S | 1 |
| Okumura, A | 1 |
| Maruyama, K | 1 |
| Negoro, T | 1 |
| Watanabe, K | 1 |
| Kojima, S | 1 |
| Brodie, MJ | 3 |
| Wade, A | 1 |
| Quelen, C | 1 |
| Guiraud-Diawara, A | 1 |
| François, C | 1 |
| Verpillat, P | 1 |
| Shen, V | 1 |
| Isojarvi, J | 1 |
| Sarangi, SC | 1 |
| Kakkar, AK | 1 |
| Hawkins, NA | 1 |
| Zachwieja, NJ | 1 |
| Miller, AR | 1 |
| Anderson, LL | 1 |
| Kearney, JA | 1 |
| Conry, JA | 1 |
| Ng, YT | 3 |
| Paolicchi, JM | 1 |
| Kernitsky, L | 1 |
| Mitchell, WG | 1 |
| Ritter, FJ | 1 |
| Collins, SD | 2 |
| Tracy, K | 1 |
| Kormany, WN | 1 |
| Abdulnabi, R | 1 |
| Riley, B | 1 |
| Stolle, J | 1 |
| Kalra, V | 1 |
| Seth, R | 1 |
| Mishra, D | 1 |
| Saha, NC | 1 |
| Wolf, P | 1 |
| Mills, JK | 1 |
| Lewis, TG | 1 |
| Mughal, K | 1 |
| Ali, I | 1 |
| Ugur, A | 1 |
| Whitehouse, WP | 1 |
| Seif-Eddeine, H | 1 |
| Nabbout, R | 1 |
| Chiron, C | 1 |
| Bailey, L | 1 |
| Malik, S | 1 |
| Gilson, C | 1 |
| Kotecha, A | 1 |
| Hernandez, A | 1 |
| Jennesson, M | 1 |
| van Eeghen, AM | 1 |
| Caruso, PA | 1 |
| Paolini, JL | 1 |
| Maschio, M | 1 |
| Dinapoli, L | 1 |
| Sperati, F | 1 |
| Pace, A | 1 |
| Fabi, A | 1 |
| Vidiri, A | 1 |
| Pompili, A | 1 |
| Carapella, CM | 1 |
| Arvio, M | 1 |
| Sipilä, I | 1 |
| Kurokawa, T | 1 |
| Héberlé, C | 1 |
| Berquin, P | 1 |
| Larnicol, N | 1 |
| Wallois, F | 1 |
| Mehndiratta, MM | 1 |
| Krishnamurthy, M | 1 |
| Rajesh, KN | 1 |
| Singh, G | 1 |
| Parmeggiani, A | 1 |
| Posar, A | 1 |
| Sangiorgi, S | 1 |
| Giovanardi-Rossi, P | 1 |
| Kosaki, K | 1 |
| Tamura, K | 1 |
| Sato, R | 1 |
| Samejima, H | 1 |
| Tanigawara, Y | 1 |
| Takahashi, T | 1 |
| Sugai, K | 1 |
| Cardinali, S | 1 |
| Granocchio, E | 1 |
| Avantaggiato, P | 1 |
| Papalia, G | 1 |
| Cagnana, A | 1 |
| Lanzi, G | 1 |
| Doi, T | 1 |
| Ueda, Y | 1 |
| Tokumaru, J | 1 |
| Willmore, LJ | 1 |
| Silva, RC | 1 |
| Montenegro, MA | 1 |
| Guerreiro, MM | 1 |
| Aylett, SE | 1 |
| Cross, H | 1 |
| Berry, D | 1 |
| Michoulas, A | 1 |
| Tong, V | 1 |
| Teng, XW | 1 |
| Chang, TK | 1 |
| Abbott, FS | 1 |
| Farrell, K | 2 |
| von Wrede, R | 1 |
| Begum, T | 1 |
| Shibasaki, H | 1 |
| Michael, B | 1 |
| Marson, AG | 2 |
| Feely, M | 4 |
| Calvert, R | 1 |
| Gibson, J | 2 |
| Gastaut, H | 3 |
| Dulac, O | 2 |
| Figueroa, D | 1 |
| Rey, E | 1 |
| Arthuis, M | 1 |
| Loiseau, P | 1 |
| Callaghan, N | 2 |
| Goggin, T | 2 |
| Allen, JW | 2 |
| Oxley, J | 3 |
| Robertson, MM | 2 |
| Trimble, MR | 4 |
| Richens, A | 2 |
| Jawad, SS | 1 |
| Aguglia, U | 3 |
| Tinuper, P | 2 |
| Gyuris, J | 1 |
| Csémi, K | 1 |
| Jawad, S | 2 |
| Wilson, A | 1 |
| Petty, R | 1 |
| Perry, A | 1 |
| Rose, FC | 1 |
| Hertrich, O | 1 |
| Shimizu, H | 1 |
| Abe, J | 1 |
| Futagi, Y | 1 |
| Onoe, S | 1 |
| Tagawa, T | 1 |
| Mimaki, T | 1 |
| Yamatodani, A | 1 |
| Kato, M | 1 |
| Kamio, M | 1 |
| Sumi, K | 1 |
| Sugita, T | 1 |
| Yabuuchi, H | 1 |
| Tedeschi, G | 2 |
| Riva, R | 2 |
| Baruzzi, A | 2 |
| Albani, F | 1 |
| Singh, A | 1 |
| Guberman, AH | 1 |
| Boisvert, D | 1 |
| Sheth, RD | 2 |
| Ronen, GM | 2 |
| Goulden, KJ | 2 |
| Penney, S | 1 |
| Bodensteiner, JB | 1 |
| O'Neill, BA | 1 |
| Bloom, DS | 1 |
| Buchanan, N | 2 |
| Remy, C | 1 |
| Schmidt, D | 1 |
| Campos, P | 1 |
| Shields, WD | 1 |
| Duncan, S | 1 |
| Gillen, GJ | 1 |
| Larkin, JG | 1 |
| McKee, PJ | 1 |
| Thompson, GG | 1 |
| Salt, SD | 1 |
| Boyd, K | 1 |
| Nakamura, F | 1 |
| Suzuki, S | 1 |
| Yagi, K | 1 |
| Seino, M | 1 |
| Fisher, R | 1 |
| Blum, D | 1 |
| De Sarro, G | 1 |
| Di Paola, ED | 1 |
| de Sarro, A | 2 |
| Grippo, J | 1 |
| Theis, JG | 1 |
| Koren, G | 1 |
| Daneman, R | 1 |
| Sherwin, AL | 1 |
| Menzano, E | 1 |
| Cortez, M | 1 |
| Hwang, P | 1 |
| De Sarro, GB | 2 |
| Berlinghieri, MC | 1 |
| Elia, M | 1 |
| Musumeci, SA | 1 |
| David, E | 1 |
| Dominijanni, A | 1 |
| Gulletta, E | 1 |
| Genton, P | 2 |
| Nguyen, VH | 1 |
| Mesdjian, E | 2 |
| Marciani, MG | 1 |
| Spanedda, F | 1 |
| Placidi, F | 1 |
| Bassetti, MA | 1 |
| Romigi, A | 1 |
| Mattia, D | 1 |
| Slamberová, R | 1 |
| Mares, P | 1 |
| Vorlícek, J | 1 |
| Selai, CE | 1 |
| Bawden, HN | 1 |
| Camfield, CS | 1 |
| Camfield, PR | 1 |
| Cunningham, C | 1 |
| Darwish, H | 1 |
| Dooley, JM | 1 |
| Gordon, K | 1 |
| Ronen, G | 1 |
| Stewart, J | 1 |
| van Mastrigt, R | 1 |
| Chadwick, DW | 1 |
| Paillard, C | 1 |
| Vanhulle, C | 1 |
| Devaux, AM | 1 |
| Ensel, P | 1 |
| Monroc-Morval, M | 1 |
| Blanc, T | 1 |
| Setterfield, JF | 1 |
| Robinson, R | 1 |
| MacDonald, D | 1 |
| Calonje, E | 1 |
| Anandam, R | 1 |
| Jan, MM | 1 |
| Shaabat, AO | 1 |
| Nakajima, H | 1 |
| Guilloton, L | 1 |
| Burckard, E | 1 |
| Fresse, S | 1 |
| Drouet, A | 1 |
| Felten, D | 1 |
| Miura, Y | 1 |
| Amano, S | 1 |
| Torii, R | 1 |
| Ihara, N | 1 |
| Bravaccio, F | 1 |
| D'Ambrosio, G | 1 |
| De Rosa, A | 1 |
| Tata, MR | 1 |
| Volpe, E | 1 |
| Rotiroti, D | 1 |
| Gratteri, S | 1 |
| Sinopoli, S | 1 |
| Juliano, M | 1 |
| Machet, L | 1 |
| Vaillant, L | 1 |
| Dardaine, V | 1 |
| Lorette, G | 1 |
| Sennoune, S | 1 |
| Bonneton, J | 1 |
| Dravet, C | 1 |
| Roger, J | 1 |
| Wildin, JD | 1 |
| Pleuvry, BJ | 1 |
| Bardy, AH | 1 |
| Seppälä, T | 1 |
| Salokorpi, T | 1 |
| Granström, ML | 1 |
| Santavuori, P | 1 |
| van Wieringen, A | 1 |
| Meijer, JW | 1 |
| van Emde Boas, W | 1 |
| Vermeij, TA | 1 |
| Guberman, A | 1 |
| Couture, M | 1 |
| Blaschuk, K | 1 |
| Sherwin, A | 1 |
| Keene, DL | 1 |
| Whiting, S | 1 |
| Humphreys, P | 1 |
| Bun, H | 1 |
| Monjanel-Mouterde, S | 1 |
| Noel, F | 1 |
| Durand, A | 1 |
| Cano, JP | 1 |
| Dávila-Gutiérrez, G | 1 |
| Mondragón-Pineda, A | 1 |
| Alcalá-Negrete, H | 1 |
| Muñoz, JJ | 1 |
| De Salamanca, RE | 1 |
| Diaz-Obregón, C | 1 |
| Timoneda, FL | 1 |
| Porter, RJ | 1 |
| Cornaggia, CM | 1 |
| Cattabeni, G | 1 |
| Cerisola, N | 1 |
| Leozappa, C | 1 |
| Mascetti, PL | 1 |
| Massironi, R | 1 |
| Porro, G | 1 |
| Manghi, E | 1 |
| Stéru, L | 1 |
| Chermat, R | 1 |
| Millet, B | 1 |
| Mico, JA | 1 |
| Simon, P | 1 |
| Scott, DF | 3 |
| Reynolds, EH | 1 |
| Heller, AJ | 1 |
| Ring, HA | 1 |
| Larrieu, JL | 1 |
| Lagueny, A | 1 |
| Ferrer, X | 1 |
| Julien, J | 1 |
| Fraser, AD | 1 |
| Isner, AF | 1 |
| Heifetz, SA | 1 |
| Haigh, JR | 2 |
| Gent, JP | 1 |
| Garratt, JC | 1 |
| Pullar, T | 2 |
| Minton, NA | 1 |
| Henry, JA | 1 |
| Frankel, RJ | 1 |
| Moffett, A | 2 |
| Peaker, S | 1 |
| Feely, MP | 1 |
| Arranz Peña, MI | 1 |
| Sanenz Lope, E | 1 |
| Vajda, FJ | 1 |
| Bladin, PF | 1 |
| Parsons, BJ | 1 |
| Cornaggia, C | 1 |
| Canevini, MP | 1 |
| Giuccioli, D | 1 |
| Pinelli, P | 1 |
| Pruneri, C | 1 |
| Canger, R | 1 |
| Trimble, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P)[NCT02565108] | Phase 2 | 20 participants (Actual) | Interventional | 2016-01-20 | Completed | ||
| Randomized, Double Blind, Placebo Controlled, Parallel Design Phase II b Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies[NCT04406948] | Phase 2 | 103 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | ||
| Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome[NCT00162981] | Phase 2 | 68 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A TEAE was defined as an adverse event with an onset date on or after the first dose of IMP. If an adverse event (AE) had a partial onset date and it was unclear from the partial date (or the stop date) whether the AE started prior to or following the first dose of IMP then the AE was considered a TEAE. The number of participants who experienced 1 or more severe TEAEs after screening up to Day 71.~A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module." (NCT02565108)
Timeframe: Postdose on Day 2 up to Safety follow-up (Day 71)
| Intervention | Participants (Count of Participants) |
|---|---|
| GWP42003-P 20 mg/kg/Day Dose | 1 |
| Placebo | 0 |
"The Cmax of CLB and its primary metabolite N-desmethylclobazam (N-CLB) was measured on Day 1 (before beginning GWP42003-P treatment; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 minutes (min), 30 min, 1 hour (h), 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h.~One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose." (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33
| Intervention | ng/mL (Geometric Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cmax: CLB Day 1 | Cmax: CLB Day 33 | Cmax: N-CLB Day 1 | Cmax: N-CLB Day 33 | Cmax: CLB Dose-normalized Day 1 | Cmax: CLB Dose-normalized Day 33 | Cmax: N-CLB Dose-normalized Day 1 | Cmax: N-CLB Dose-normalized Day 33 | |
| GWP42003-P 20 mg/kg/Day Dose | 330 | 329 | 2060 | 4570 | 19.3 | 19.2 | 121 | 267 |
| Placebo | 440 | 461 | 1130 | 1320 | 22.0 | 23.1 | 56.6 | 66.1 |
"The AUCtau of CLB and its primary metabolite N-CLB was measured on Day 1 (before first GWP42003-P dose; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h.~One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose." (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33
| Intervention | h*ng/mL (Geometric Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| AUCtau: CLB Day 1 | AUCtau: CLB Day 33 | AUCtau: N-CLB Day 1 | AUCtau: N-CLB Day 33 | AUCtau: CLB Dose-normalized Day 1 | AUCtau: CLB Dose-normalized Day 33 | AUCtau: N-CLB Dose-normalized Day 1 | AUCtau: N-CLB Dose-normalized Day 33 | |
| GWP42003-P 20 mg/kg/Day Dose | 2690 | 2840 | 18300 | 48400 | 157 | 166 | 1070 | 2830 |
| Placebo | 3320 | 3310 | 11400 | 11500 | 166 | 165 | 571 | 573 |
The Day 33 compared to Day 1 geometric mean ratios of CLB and N-CLB were calculated for AUCtau to look for evidence of drug-drug interactions between GWP42003-P/Placebo and CLB and between GWP42003-P/Placebo and N-CLB. A standard 90% CI approach for the between time point ratios of geometric means of AUCtau was carried out on a logarithmic scale using a linear mixed effect model. The no-effect boundary was set between 0.5 and 2.0, and if the 90% CI for the ratio of the geometric means of a PK variable fell within the interval [0.5, 2.0], a lack of meaningful effect was declared. Estimates were back transformed to provide summaries on the original scale. The model included a fixed effect term for PK assessment period. An unstructured covariance matrix was used. Kenward and Roger's method was used to calculate the denominator degrees of freedom for the fixed effects. (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33
| Intervention | Ratio (Number) | |
|---|---|---|
| Geometric Mean Ratio of CLB, AUCtau | Geometric Mean Ratio of N-CLB, AUCtau | |
| GWP42003-P 20 mg/kg/Day Dose | 1.06 | 2.64 |
| Placebo | 0.996 | 1.00 |
The Day 33 compared to Day 1 geometric mean ratios of CLB and N-CLB were calculated for Cmax to look for evidence of drug-drug interactions between GWP42003-P/Placebo and CLB and between GWP42003-P/Placebo and N-CLB. A standard 90% confidence interval (CI) approach for the between time point ratios of geometric means of Cmax was carried out on a logarithmic scale using a linear mixed effect model. The no-effect boundary was set between 0.5 and 2.0, and if the 90% CI for the ratio of the geometric means of a PK variable fell within the interval [0.5, 2.0], a lack of meaningful effect was declared. Estimates were back transformed to provide summaries on the original scale. The model included a fixed effect term for PK assessment period. An unstructured covariance matrix was used. Kenward and Roger's method was used to calculate the denominator degrees of freedom for the fixed effects. (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33
| Intervention | Ratio (Number) | |
|---|---|---|
| Geometric Mean Ratio of CLB, Cmax | Geometric Mean Ratio of N-CLB, Cmax | |
| GWP42003-P 20 mg/kg/Day Dose | 0.997 | 2.22 |
| Placebo | 1.05 | 1.17 |
"The tmax of CLB and its primary metabolite N-CLB was measured on Day 1 (before beginning GWP42003-P treatment; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h.~One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose." (NCT02565108)
Timeframe: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33
| Intervention | h (Median) | |||
|---|---|---|---|---|
| tmax: CLB Day 1 | tmax: CLB Day 33 | tmax: N-CLB Day 1 | tmax: N-CLB Day 33 | |
| GWP42003-P 20 mg/kg/Day Dose | 1.00 | 1.86 | 1.50 | 3.03 |
| Placebo | 1.17 | 1.58 | 2.00 | 1.00 |
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and the 4-week maintenance period
| Intervention | Percent Reduction (Median) |
|---|---|
| Clobazam Low Dose | 29 |
| Clobazam High Dose | 93 |
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and 4-week maintenance period
| Intervention | Percent Reduction (Mean) |
|---|---|
| Clobazam Low Dose | 10.1 |
| Clobazam High Dose | 85.2 |
"The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse." (NCT00162981)
Timeframe: Week 3
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very Much Improved | Much Improved | Minimally Improved | No Change | Minimally Worse | Much Worse | Very Much Worse | |
| Clobazam High Dose | 15 | 15 | 1 | 0 | 1 | 0 | 0 |
| Clobazam Low Dose | 7 | 9 | 9 | 3 | 0 | 1 | 0 |
"The parent/caregiver was asked to rate the patient's overall change in symptoms and overall change in seizure activity and Quality of Life since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse." (NCT00162981)
Timeframe: Week 7
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Very Much Improved | Much Improved | Minimally Improved | No Change | Minimally Worse | Much Worse | Very Much Worse | |
| Clobazam High Dose | 16 | 11 | 1 | 0 | 1 | 0 | 0 |
| Clobazam Low Dose | 6 | 6 | 10 | 5 | 1 | 0 | 0 |
Number of drop seizures (average per week) was obtained from seizure diaries. The average drop in seizures per week for patients who did not complete the maintenance period was calculated based on the time from the beginning of the maintenance period to date of withdrawal. (NCT00162981)
Timeframe: 4-week baseline period and 4-week maintenance period
| Intervention | Percent of participants (Number) | |||
|---|---|---|---|---|
| ≥ 25% reduction | ≥ 50% reduction | ≥ 75% reduction | 100% reduction | |
| Clobazam High Dose | 32 | 30 | 23 | 8 |
| Clobazam Low Dose | 18 | 12 | 7 | 2 |
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
24 reviews available for clobazam and Epilepsy
| Article | Year |
|---|---|
Pharmacokinetic Drug-Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients.
Topics: Anticonvulsants; Cannabidiol; Carbamazepine; Clobazam; COVID-19; COVID-19 Drug Treatment; Drug Inter | 2021 |
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve | 2022 |
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Topics: Adult; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug Resistant Epilepsy; Epilepsies, Myoclonic | 2023 |
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsy; Fructose; Humans; Induct | 2014 |
Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Clobazam; Drug Discovery; Epilepsy; Humans | 2015 |
Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clobazam; Drug Interactions; Electroence | 2012 |
Stiripentol: an example of antiepileptic drug development in childhood epilepsies.
Topics: Anticonvulsants; Benzodiazepines; Child; Clobazam; Cytochrome P-450 Enzyme System; Dioxolanes; Epile | 2012 |
Clobazam.
Topics: Animals; Anticonvulsants; Benzodiazepines; Brain; Clinical Trials as Topic; Clobazam; Epilepsy; Huma | 2007 |
Clobazam as an add-on in the management of refractory epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Humans; Randomized Controlled Trials as Topic | 2008 |
[Benzodiazepines in the treatment of epilepsy].
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child, Preschool; Clobazam | 1983 |
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1995 |
New anti-epileptic drugs in the 1990s.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1994 |
Clobazam in the treatment of epilepsy: a review of the literature.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Dose-Response Re | 1994 |
Clobazam for treatment of intractable epilepsy: a critical assessment.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinical Trials a | 1994 |
Investigational antiepileptic drugs for the treatment of childhood seizure disorders: a review of efficacy and safety.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Clinical Trials as | 1994 |
Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Cl | 1995 |
[Treatment of the epilepsy: new drugs].
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz | 1996 |
Fortnightly review: drug treatment of epilepsy.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Barbiturates; Benzodiazepines; Clobazam; Clo | 1999 |
Clobazam in epilepsy.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Epilepsy; Humans | 2000 |
Epileptic encephalopathy.
Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain Diseases; Chil | 2001 |
[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug].
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clobazam; | 2001 |
On the use of tranquillisers in epilepsy.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Humans; Tranquilizing Age | 2002 |
Adjunctive therapy in resistant epilepsy.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Resistance; | 1988 |
Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Child; Child, Pre | 1986 |
25 trials available for clobazam and Epilepsy
| Article | Year |
|---|---|
A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
Topics: Adult; Anticonvulsants; Cannabidiol; Clobazam; Double-Blind Method; Drug Interactions; Drug Therapy, | 2020 |
Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*).
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Clobazam; Electroencephalography; Epilepsy; Europe | 2020 |
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Diazepam; Dru | 2021 |
Response to clobazam in continuous spike-wave during sleep.
Topics: Adolescent; Benzodiazepines; Brain Waves; Child; Child, Preschool; Clobazam; Cognition; Electroencep | 2018 |
Clinical and electrocorticographic response to antiepileptic drugs in patients treated with responsive stimulation.
Topics: Adolescent; Adult; Anticonvulsants; Clobazam; Electrocorticography; Epilepsy; Female; Humans; Lacosa | 2018 |
Clobazam in the treatment of Lennox-Gastaut syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Developmenta | 2009 |
Acute administration of benzodiazepines as part of treatment strategies for epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Clobazam; Diazepam; Dr | 2011 |
Clobazam monotherapy in drug naïve adult patients with epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Female | 2003 |
Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB.
Topics: Adult; Anticonvulsants; Benzodiazepines; Clobazam; Dose-Response Relationship, Drug; Epilepsy; Femal | 2007 |
Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants.
Topics: Acute Disease; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinical Tr | 1982 |
Clobazam as adjunctive treatment in drug resistant epilepsy--report on an open prospective study.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; | 1984 |
Intermittent clobazam for catamenial epilepsy: tolerance avoided.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinical Trials as | 1984 |
Clobazam as adjunctive treatment in refractory epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clinica | 1983 |
Antiepileptic effects of clobazam in children.
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child, | 1982 |
Lack of effect of concomitant clobazam on interictal 123I-iomazenil SPECT.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Brain; Clobazam; Ep | 1993 |
Aggression in children treated with clobazam for epilepsy.
Topics: Aggression; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child B | 1994 |
Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy.
Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; C | 1998 |
Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value?
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexanecarbox | 1998 |
The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Canadian Study Group for Childhood Epilepsy.
Topics: Adolescent; Adolescent Behavior; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepin | 1999 |
Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations.
Topics: Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Dos | 1990 |
Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood.
Topics: Adolescent; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Child, Preschool; Clobaz | 1990 |
Intractable epilepsies. An open trial with Clobazam.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clinical Trials as Topic | 1989 |
Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; | 1987 |
Current status of the 1,4- and 1,5-benzodiazepines in the treatment of epilepsy: the place of clobazam.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Child; Child, Pre | 1986 |
Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; | 1985 |
110 other studies available for clobazam and Epilepsy
| Article | Year |
|---|---|
Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience.
Topics: Adult; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Humans; Male; Prospective Studies; Seiz | 2022 |
The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study.
Topics: Anticonvulsants; Child; Clobazam; Cohort Studies; Epilepsy; Humans; Retrospective Studies; Seizures; | 2022 |
Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach.
Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Epilepsy; Levetiracetam; Male; M | 2022 |
Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug-Related Side Effects an | 2023 |
A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy.
Topics: Anticonvulsants; Clobazam; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C | 2023 |
Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet.
Topics: Anticonvulsants; Child; Clobazam; Diet, Ketogenic; Drug Resistant Epilepsy; Epilepsy; Humans; Infant | 2023 |
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies.
Topics: Clobazam; Drug Resistant Epilepsy; Epilepsy; gamma-Aminobutyric Acid; Humans; Precision Medicine; Pr | 2023 |
Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography.
Topics: Biomarkers; Clobazam; Deep Brain Stimulation; Drug Resistant Epilepsy; Electrocorticography; Epileps | 2023 |
Gestational Exposure to Benzodiazepines, 3: Clobazam and Major Congenital Malformations.
Topics: Abnormalities, Drug-Induced; Anxiety Disorders; Benzodiazepines; Clobazam; Drug Therapy, Combination | 2019 |
Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: A case report on a potential new direction in personalised medicine.
Topics: Anticonvulsants; Clobazam; Enterovirus A, Human; Enterovirus Infections; Epilepsy; Fatal Outcome; Fe | 2020 |
Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Dioxolanes; | 2020 |
Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database.
Topics: Anticonvulsants; Carbamazepine; Clobazam; Clonazepam; Databases, Factual; Drug Therapy, Combination; | 2020 |
Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Clobazam; Drug Therapy, Combination; Epilepsy; Female | 2021 |
CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clobazam; Drug Therapy, Combination; Epilepsie | 2022 |
Interactions between cannabidiol and commonly used antiepileptic drugs.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Cannabidiol; Child; Child, Prescho | 2017 |
A longitudinal cohort study on the impact of the clobazam shortage on patients with epilepsy.
Topics: Adolescent; Adult; Aged; Alberta; Anticonvulsants; Benzodiazepines; Clobazam; Cohort Studies; Commun | 2018 |
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Topics: Adolescent; Anticonvulsants; Attention; Cannabidiol; Cannabis; Child; Child, Preschool; Clobazam; Dr | 2018 |
Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; | 2018 |
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures.
Topics: Adult; Anticonvulsants; Clobazam; Electroencephalography; Epilepsy; Humans; Patient Discharge; Retro | 2019 |
Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Asian People; Benzodiazepines; Cl | 2013 |
Electroconvulsive therapy for psychosis in a patient with epilepsy related to hypothalamic hamartoma.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clobazam; Delusions; Drug Resistance; Electr | 2013 |
Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Body Weight; Child; Child, Preschool; Clobazam; | 2014 |
Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.
Topics: Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Cytochrome P-450 CYP2C19 | 2014 |
Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Dose-Response Relat | 2014 |
Intermittent clobazam prophylaxis in hot water epilepsy is safe and effective: a prospective study.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Electroencep | 2014 |
Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; | 2014 |
Clobazam: the phoenix drug (from the very old to the brand new).
Topics: Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Female; Humans; Male | 2014 |
Effect of clobazam as add-on antiepileptic drug in patients with epilepsy.
Topics: Adolescent; Adult; Ambulatory Care; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Cloba | 2014 |
Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Asian People; Benzodiazepines; Clobazam; Cytochrome P-450 | 2015 |
Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
Topics: Age of Onset; Anticonvulsants; Autistic Disorder; Benzodiazepines; Cadherins; Child; Clobazam; Cogni | 2015 |
Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series.
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Child; Clobazam; Clonazepam; Epilepsy; Female; Humans | 2014 |
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
Topics: Adolescent; Benzodiazepines; Cannabidiol; Child; Child, Preschool; Clobazam; Cytochrome P-450 Enzyme | 2015 |
Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Child; Ch | 2016 |
Clobazam-induced pedal edema: "An unrecognized side effect of a common antiepileptic drug".
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Clobazam; Edema; Epilepsy; Female; Foot; Humans; Male | 2016 |
The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Child, Preschool; Clobazam; Clon | 2016 |
Clobazam and clonazepam use in epilepsy: Results from a UK database incident user cohort study.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; | 2016 |
Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Body Composition; Body Water; Body Weight; Carbamazepine; C | 2016 |
Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq.
Topics: Animals; Benzodiazepines; Chromosome Mapping; Chromosomes; Clobazam; Disease Models, Animal; Epileps | 2016 |
Clobazam in refractory childhood epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Child; Clobazam; Drug Resistance; Drug Therapy, Combination; Epile | 2010 |
Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year.
Topics: Adolescent; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Exanthema; Female; Fructos | 2011 |
Clobazam for the treatment of intractable epilepsy in children.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Female; F | 2013 |
Clobazam therapy of refractory epilepsy in tuberous sclerosis complex.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Humans; M | 2013 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
[Psychomotor slowness of a mentally retarded woman].
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexan | 2001 |
[Clinical features and treatment of refractory epilepsy in children].
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam | 2001 |
Vagus nerve stimulation in a case of epilepsy with CSWSS: respiratory side effects during sleep.
Topics: Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Clobazam; Combined Modali | 2002 |
Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.
Topics: Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Child; Clobazam; Cytochrome P-450 C | 2004 |
A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Child; Child, Pr | 2004 |
Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan.
Topics: Anticonvulsants; Benzodiazepines; Clobazam; Clorazepate Dipotassium; Dose-Response Relationship, Dru | 2004 |
Motor impairment on awakening in a patient with an EEG pattern of "unilateral, continuous spikes and waves during slow sleep".
Topics: Anticonvulsants; Arm; Benzodiazepines; Child; Clobazam; Electroencephalography; Epilepsy; Ethosuximi | 2005 |
Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats.
Topics: Amino Acid Transport System X-AG; Analysis of Variance; Animals; Anticonvulsants; Benzodiazepines; B | 2005 |
Clobazam as add-on therapy in children with epileptic encephalopathy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Brain; Child; Child, Preschool; Clobazam; Dose-Respons | 2006 |
Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Dose-Response Relationship, Drug; Epil | 2006 |
Oxidative stress in children receiving valproic acid.
Topics: Adolescent; Age Factors; Anticonvulsants; Benzodiazepines; Biomarkers; Canada; Carbamazepine; Case-C | 2006 |
[Epilepsy: which therapy in acute care?].
Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Clobazam; Clonazepam; Diazepam; Epilepsy; Humans; L | 2006 |
The effects of benzodiazepines on chronic epilepsy in man.
Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Electroencephalography; Epilepsy; | 1982 |
[Monotherapy with clobazam in epilepsies in children].
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child, | 1983 |
Startle-induced epileptic seizures.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Child, Preschool; | 1984 |
[Eating epilepsy].
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Ther | 1984 |
Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama | 1984 |
Paroxysmal language disturbance in an epileptic treated with clobazam.
Topics: Adolescent; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; Humans; Mal | 1983 |
[Ataractic treatment in psychiatry and general medicine. Overview of preparations, 3].
Topics: Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Benzodiazepinones; Chlorprothixene; Clobaza | 1983 |
Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; | 1981 |
Quantitative determination of clobazam in the plasma of epileptic patients by gas-liquid chromatography with electron-capture detection.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chromatography, Gas; Cloba | 1981 |
Clobazam in long-term epilepsy treatment: sustained responders versus those developing tolerance.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Ther | 1995 |
Clobazam for intractable pediatric epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cerebra | 1995 |
[Clobazam use in refractory epilepsies in children].
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chemotherapy, Adjuvant; Ch | 1993 |
Clobazam in the treatment of epilepsy: prospective follow-up to 8 years.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; | 1993 |
Peripheral benzodiazepine receptors in platelets of epileptic patients.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; B | 1993 |
The use of clobazam in uncontrolled epilepsy.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carcinoma, Renal Cell; Clo | 1995 |
Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Cells, Cultured; | 1996 |
Tolerance to anticonvulsant effects of some benzodiazepines in genetically epilepsy prone rats.
Topics: Acoustic Stimulation; Administration, Oral; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiaz | 1996 |
Interactions of clobazam with conventional antiepileptics in children.
Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; C | 1997 |
Does antiepileptic therapy affect immune response?
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama | 1998 |
Carbamazepine intoxication with negative myoclonus after the addition of clobazam.
Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Cloba | 1998 |
Changes of the EEG paroxysmal pattern during felbamate therapy in Lennox-Gastaut syndrome: a case report.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Drug Therapy, | 1998 |
Clobazam exerts an anticonvulsant action in immature rats.
Topics: Aging; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Electric Stimulatio | 1998 |
Report of a pragmatic trial comparing clobazam and "standard" treatment in childhood epilepsy.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Canada; Child; Clobazam; Epilepsy; Humans; Pa | 1999 |
[Recurrence of herpes simplex encephalitis].
Topics: Acyclovir; Anti-Anxiety Agents; Anti-Inflammatory Agents; Anticonvulsants; Antiviral Agents; Benzodi | 1999 |
Coma-induced bullae and sweat gland necrosis following clobazam.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Coma; Epilepsy; F | 2000 |
Clobazam for the treatment of intractable childhood epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Cohort Studies; Epi | 2000 |
[Epileptic crisis after antimalaria chemoprophylaxis with chloroquine].
Topics: Anti-Anxiety Agents; Anticonvulsants; Antimalarials; Benzodiazepines; Chloroquine; Clobazam; Epileps | 2001 |
Clobazam shows a different antiepileptic action profile from clonazepam and zonisamide in Ihara epileptic rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Circadian Rhythm; Clobazam; Clonazep | 2002 |
[The anti-epileptic properties of a diazepine drug (clobazam). Preliminary results].
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Clobazam; Epilepsy; Epilepsy, | 1979 |
Tolerance to anticonvulsant effects of clobazam, diazepam, and clonazepam in genetically epilepsy prone rats.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepino | 1992 |
Patch testing with clobazam: relapse of generalized drug eruption.
Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Erupt | 1992 |
Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama | 1992 |
Tolerance to the anticonvulsant effects of clobazam in mice.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepino | 1992 |
Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy.
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Child, | 1991 |
Pilot study to determine the interaction of oxiracetam with antiepileptic drugs.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Clob | 1990 |
Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam.
Topics: Adolescent; Adult; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepin | 1990 |
[Usefulness of clobazam in the treatment of refractory epilepsy in children].
Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chemical Pheno | 1990 |
The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Chromatogra | 1990 |
Mechanisms of action of new antiepileptic drugs.
Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants; | 1989 |
Oral benzodiazepines as prophylaxis for epilepsy.
Topics: Administration, Oral; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Clonazepam; | 1986 |
Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epileps | 1986 |
Clobazam in chronic epilepsy.
Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; Humans | 1988 |
Clobazam for epilepsy.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chronic | 1988 |
[Epilepsy with continuous discharges during slow-wave sleep. Treatment with clobazam].
Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Carbamazepine; Child; Child, Preschool; Clo | 1986 |
Tissue distribution of ethosuximide and clobazam in a seizure related fatality.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Chromatography, Gas | 1988 |
Disappointing results of increasing benzodiazepine dose after the development of anticonvulsant tolerance.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Dose-Resp | 1988 |
Fatal paracetamol poisoning in an epileptic.
Topics: Acetaminophen; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Cytochrome | 1988 |
The long-term effect of clobazam as adjunctive therapy in epilepsy.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Brain; Clobazam; Electroencephalogra | 1988 |
Use of clobazam in certain forms of status epilepticus and in startle-induced epileptic seizures.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child, Preschool; Clobaz | 1986 |
On the anticonvulsant and psychotropic properties of clobazam--a preliminary study.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; Female; Humans; | 1986 |
Benzodiazepines in the treatment of children with epilepsy.
Topics: Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Child, Preschool; Clobazam; Clonazep | 1986 |
Determination of clobazam and its N-demethyl metabolite in serum of epileptic patients.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chromatography, Gas; Cloba | 1986 |
Monotherapy and polytherapy for intractable epilepsies.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Clobazam; D | 1985 |
Development of tolerance to anticonvulsant effect of clobazam.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Therapy, Co | 1985 |